Suppr超能文献

马的培高利特中毒:病例系列

Equine Pergolide Toxicity: A Case Series.

作者信息

Ebeling-Koning Natalie E, Fowler John T, DelBianco John D, Surmaitis Ryan M

机构信息

Department of Emergency and Hospital Medicine, Lehigh Valley Health Network/University of South Florida (USF) Morsani College of Medicine, Allentown, USA.

出版信息

Cureus. 2024 Jul 10;16(7):e64265. doi: 10.7759/cureus.64265. eCollection 2024 Jul.

Abstract

Veterinary medication exposure may result in human toxicity, with approximately 6,000 exposures to veterinary-only medications reported to poison centers in 2022. There is a paucity of literature on the management of poisoned patients secondary to pharmaceuticals intended for equine use. Pergolide is a dopamine and serotonin receptor agonist and is currently approved to treat equine Cushing's disease. It was previously approved in the United States (US) to treat Parkinson's disease in humans; however, it was withdrawn from the market in 2007 due to its association with valvular heart disease. We report two cases of pergolide toxicity in horse owners following unintentional ingestions. Both patients experienced similar clinical presentations resulting from their unintentional pergolide ingestions. Veterinary medication ingestion presents a unique challenge to clinicians as the drug may have limited human toxicity data and/or recommended animal dosing may differ greatly from human dosing. Case reports of human toxicity may assist with anticipating the clinical course and guiding medical decision-making.

摘要

接触兽药可能导致人体中毒,2022年约有6000例仅用于兽医用药的接触事件报告给了中毒控制中心。关于因用于马匹的药物导致中毒患者的管理,相关文献匮乏。培高利特是一种多巴胺和5-羟色胺受体激动剂,目前被批准用于治疗马的库兴氏病。它曾在美国被批准用于治疗人类帕金森病;然而,由于其与心脏瓣膜病有关联,于2007年退出市场。我们报告了两例马匹主人因意外摄入培高利特而中毒的病例。两名患者因意外摄入培高利特而出现了相似的临床表现。兽药摄入给临床医生带来了独特的挑战,因为该药物可能人类毒性数据有限,和/或推荐的动物剂量可能与人类剂量有很大差异。人类中毒的病例报告可能有助于预测临床病程并指导医疗决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf6/11315443/90ba6e590286/cureus-0016-00000064265-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验